稳定期慢性阻塞性肺疾病患者血清可溶性髓样细胞触发受体-1的检测及临床意义  

The Detection and Clinical Value of Soluble Triggering Receptor Expressed on Myeloid Cells-1in Patients with Stable Chronic Obstructive Pulmonary Disease

作　　者：吴娟[1] 沙杭[1] 

机构地区：[1]南方医科大学,广州市510515

出　　处：《实用医学杂志》2016年第10期1609-1612,共4页The Journal of Practical Medicine

基　　金：军队十二五医药卫生保健专项基金项目(编号:14BJZ045)

摘　　要：目的:探讨可溶性髓样细胞触发受体-1(s TREM-1)对稳定期慢性阻塞性肺疾病(s COPD)病情的评估作用。方法:选取2015年1月至2015年8月于我院就诊的s COPD患者101例作为观察组,同期选取健康查体者81例作为对照组。所有研究对象均行肺功能检查记录FEV1%pred、采集外周静脉血检测血清s TREM-1;对s COPD患者进行动脉血气分析与COPD患者自我评估测试(CAT)。结果 :s COPD组血清s TREM-1水平显著高于对照组[(113.2±31.5)pg/m L vs.(83.8±17.9)pg/m L,P=0.000]。s COPD患者血清s TREM-1水平与CAT评分呈正相关(r=0.507,P=0.000),与Pa O2、FEV1%pred呈显著负相关(r=-0.439,P=0.000;r=-0.560,P=0.000)。结论 :血清s TREM-1具有评估s COPD患者严重程度的潜在价值。Objective To determine the value of soluble triggering receptor expressed on myeloid cells 1（s TREM-1） in patients with stable chronic obstructive pulmonary disease（s COPD）. Methods From 2015 January to 2015 August, 101 patients with stable chronic obstructive pulmonary disease and 81 healthy controls were enrolled. All subjects underwent pulmonary function test to record FEV1% pred and FEV1% FVC and their serum s TREM-1 levels were determined. Arterial blood gas analyses and COPD assessment tests were also conducted in stable COPD patients. Results Serum s TREM-1 levels were significantly higher in stable COPD patients than healthy controls（113.2 ± 31.5 pg / m L and 83.8 ± 17.9 pg / m L respectively, P = 0.000）. s TREM-1 levels were positively correlated with CAT score（r = 0.507, P = 0.000）, whereas negatively correlated with FEV1%pred and Pa O2（r = 0.507, P = 0.000; r = 0.439, P = 0.000）. Conclusion s TREM-1 is a promising biomarker to evaluate s COPD in the future.

关 键 词：肺疾病 慢性阻塞性 炎症 可溶性髓样细胞触发受体-1 

分 类 号：R563.9[医药卫生—呼吸系统]